Title
Role of mitochondrial ATP-sensitive potassium channel-mediated PKC-ε in delayed protection against myocardial ischemia/reperfusion injury in isolated hearts of sevoflurane-preconditioned rats.

Permalink
https://escholarship.org/uc/item/8th5h9v7

Journal
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 48(6)

ISSN
0100-879X

Authors
Wang, C
Hu, SM
Xie, H
et al.

Publication Date
2015-06-01

DOI
10.1590/1414-431x20143876

Peer reviewed
Role of mitochondrial ATP-sensitive potassium channel-mediated PKC-ε in delayed protection against myocardial ischemia/reperfusion injury in isolated hearts of sevoflurane-preconditioned rats

C. Wang1,2*, S.M. Hu2*, H. Xie1, S.G. Qiao1, H. Liu3 and C.F. Liu2

1Department of Anesthesiology and Critical Care, The Second Affiliate Hospital, Soochow University, Suzhou, China
2Institute of Neuroscience, Soochow University, Suzhou, China
3Department of Anesthesiology and Pain Medicine, University of California Davis Health System, Davis, CA, USA

Abstract

This study aimed to determine the role of mitochondrial adenosine triphosphate-sensitive potassium (mitoKATP) channels and protein kinase C (PKC)-ε in the delayed protective effects of sevoflurane preconditioning using Langendorff isolated heart perfusion models. Fifty-four isolated perfused rat hearts were randomly divided into 6 groups (n=9). The rats were exposed for 60 min to 2.5% sevoflurane (the second window of protection group, SWOP group) or 33% oxygen inhalation (I/R group) 24 h before coronary occlusion. The control group (CON) and the sevoflurane group (SEVO) group were exposed to 33% oxygen and 2.5% sevoflurane for 60 min, respectively, without coronary occlusion. The mitoKATP channel inhibitor 5-hydroxydecanoate (5-HD) was given 30 min before sevoflurane preconditioning (5-HD+SWOP group). Cardiac function indices, infarct sizes, serum cardiac troponin I (cTnI) concentrations, and the expression levels of phosphorylated PKC-ε (p-PKC-ε) and caspase-8 were measured. Cardiac function was unchanged, p-PKC-ε expression was upregulated, caspase-8 expression was downregulated, cTnI concentrations were decreased, and the infarcts were significantly smaller (P<0.05) in the SWOP group compared with the I/R group. Cardiac function was worse, p-PKC-ε expression was downregulated, caspase-8 expression was upregulated, cTnI concentration was increased and infarcts were larger in the 5-HD+SWOP group (P<0.05) compared with the SWOP group. The results suggest that mitoKATP channels are involved in the myocardial protective effects of sevoflurane in preconditioning against I/R injury, by regulating PKC-ε phosphorylation before ischemia, and by downregulating caspase-8 during reperfusion.

Key words: Ischemia; Reperfusion; mitoKATP channel; Preconditioning; Protein kinase C

Introduction

Myocardial ischemia/reperfusion (I/R) injury occurs not only in coronary heart disease but also as a complication of cardiac surgery performed to treat lethal reperfusion injury, myocardial stunning, reperfusion arrhythmias, and vascular injury. I/R injury is a significant factor in perioperative complications and increased mortality (1). Therefore, preventing myocardial I/R injury in noncardiac surgery patients and nonsurgical cardiac ischemia may decrease the incidence of cardiac complications.

Repeated short episodes of myocardial ischemia, called myocardial ischemic preconditioning (IPC), reduce the occurrence of myocardial I/R injury (2). However, ischemic pretreatment is difficult to implement clinically. Anesthetic preconditioning (APC) with inhaled anesthetics that are widely used in clinical anesthesia was first reported in 1997 to protect the myocardium from I/R injury (3). Since then, numerous studies have shown that inhaled anesthetics simulate ischemic preconditioning to reduce myocardial I/R injury, which has clinically significant implications (4-6). APC lowers the risk of myocardial ischemia, is readily available, and is convenient to apply, making it a good alternative to ischemic...
drugs and methods. APC is especially suitable for preoperative inhalational anesthetic pretreatment for myocardial I/R injury. Inhalational anesthetic pretreatment may trigger the release of a variety of endogenous bioactive substances in myocardial or brain tissue through cell membrane receptor binding or through direct activation of intracellular signaling pathways involving a variety of cell types and protective substances. Although numerous studies have focused on APC, its specific mechanism of action has not yet been fully elucidated (7). This study focused on the mechanism underlying the protective effect of APC.

Opening of mitochondrial ATP-sensitive potassium (mitoKATP) channels plays an important role in protecting against myocardial ischemic disease (8) and is known to occur during APC (9,10). Recent studies have found that mitoKATP channels are involved in the mitochondrial membrane cascade-signaling pathway during myocardial ischemic preconditioning (11). The mitoKATP channel-specific blocker 5-hydroxydecanoate (5-HD) blocks the myocardial protective effect of ischemic and pharmacological preconditioning (12,13). Pretreating nerve cells with diazoxide, a selective opener of mitoKATP channels, induces the phosphorylation of protein kinase C (PKC)-ε, as well as the opening of mitoKATP channels, thereby forming a system of positive feedback regulation (14). A recent study of the effects of theaflavins revealed that cardiac muscle contractility depends on PKC-ε concentration (15).

The delayed protective effects of sevoflurane preconditioning can effectively limit peri- and post-operative complications of cardiac surgery. This study utilized the Langendorff isolated heart perfusion model to investigate the effects of mitoKATP channel-mediated PKC-ε in relation to the delayed protective effects of sevoflurane preconditioning.

Material and Methods

Animals

The Committee of the Medical College of Soochow University (Suzhou, China; License No. 20020008, Grade II) approved the use of healthy clean-grade male Sprague-Dawley (SD) rats that were maintained in their Experimental Animal Center for this study.

Experimental protocol

The Committee for Experimental Animals of the Medical College of Soochow University, Suzhou, China (Chairperson, Professor Zhi-mou Xue; No. SZULL-20090309) approved the study protocol on March 9, 2009.

A total of 54 rats were randomly assigned to 6 groups (n = 9/group): Rats given 33% oxygen or 2.5% sevoflurane for 60 min without occlusion and reperfusion 24 h later served as the control (CON) and sevoflurane (SEVO) groups, respectively. Rats in the I/R group were given 33% oxygen for 60 min followed by a 30 min equilibration period, 30 min of occlusion, and 2 h of reperfusion 24 h later. Rats in the SWOP (second window of protection) group were given an intraperitoneal injection of 10 mg/kg 5-HD (a selective mitoKATP channel antagonist; H135, Sigma, USA) 30 min before inhalation of 2.5% sevoflurane, followed by a 30 min equilibration period, 30 min of occlusion, and 2 h of reperfusion 24 h later. Rats in the 5-HD group were given an intraperitoneal injection of 10 mg/kg 5-hydroxydecanoate without inhalation of sevoflurane followed by a 30 min equilibration period, 30 min of occlusion, and 2 h of reperfusion 24 h later. The CON and SEVO groups did not undergo occlusion and reperfusion. The I/R, SWOP, 5-HD + SWOP, and 5-HD groups underwent occlusion and reperfusion.

Cardiac function indices of the rats in all groups were recorded. Myocardial infarct size was measured by triphenyl tetrazolium chloride (TTC) staining. Cardiac troponin I (cTnI) concentration in the coronary transudate was measured by an enzyme-linked immunosorbent assay (ELISA). The expression levels of phosphorylated PKC-ε (p-PKC-ε) and caspase-8 were assayed by Western blot. Rats that developed CO2 accumulation during sevoflurane preconditioning, refractory ventricular fibrillation, frequent recurrent arrhythmia, left ventricle systolic pressure (LVSP) <80 mmHg, or heart rate (HR) <200 bpm were excluded from the experiment.

Sevoflurane preconditioning

Rats were placed in a glass box connected to the gas flow inlet of a Sevotec 5 sevoflurane vaporizer (Drager Vapor 2000, Drager Medical, Germany) (16). The box was continuously infused with 2.5% sevoflurane (h20090714, Abbott Pharmaceutical, China) and 97.5% oxygen at a flow of 2 L/min. An anesthesia monitor (ULT-I type, Datex-Ohmeda, USA) was connected to monitor the concentrations of sevoflurane, O2, and CO2. The rats were placed in the glass box for 1 h after the sevoflurane concentration had reached approximately 1.0 MAC (monitored anesthesia care), after which they were returned to their cages and fed a normal diet.

Langendorff isolated heart perfusion model

Krebs-Henseleit (K-H) solution, consisting of 118.0 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 25.0 mM NaHCO3, 1.2 mM MgSO4, 2.5 mM CaCl2, and 11.0 mM glucose was prepared. The pH was adjusted to 7.35-7.45, and the mixture was heated to 36.0 °C on a temperature-controlled mechanical stirrer (90-3 type, Huxi Analysis Instrument, China). A pre-access test was conducted for 30 min to ensure that the 95% O2 and 5% CO2 gas was fully mixed with the K-H solution. A temperature-controlled water bath (ZC-10, Alcott Biotechnology Co., Ltd., China) was used to maintain
the external circulation temperature at 36°C. The rats were intraperitoneally anesthetized with 50 mg/kg pento- 
arbarbitral sodium (060928, Haitai Riel Biotechnology, China), followed by 500 U/kg of heparin. The rat hearts were quickly excised and mounted on a Langendorff apparatus via the aorta for retrograde perfusion with the K-H solution at a constant pressure of 10 kPa. The aorta of the hearts was tied with 5-0 silk to produce global ischemia. (17). The pump was adjusted to maintain a coronary flow rate of 12 mL/min. A cuff pressure transducer (YP200, SIA Industrial and Trade, China) was inserted into the left ventricle to monitor heart function. The cuff volume was adjusted to maintain a stable left ventricular end diastolic pressure (LVEDP) of 6-10 mmHg during initial equilibration.

Cardiac function
Cardiac function indices including LVSP, LVEDP, the maximal rate of rise of ventricular pressure (±dP/dtmax), and HR were monitored after 30 min of equilibration (T0), and then at 30 (T1), 60 (T2), 90 (T3), and 120 min (T4) after reperfusion using the Med Lab 6.0 software on a U/4C501H Med Lab biological signal acquisition and processing system (Mei Yi Technology, China).

Infarct size determination and cardiac troponin I
After 2 h of reperfusion, the heart was removed and cooled at −80°C for 5 min. The heart was then cut into 6 cross-sectional slices of 2-mm thickness that were incubated at 37°C for 15 min in 1% TTC (T8877, Sigma) in 0.1 M phosphate buffer, pH 7.4 and fixed overnight in 10% formaldehyde. The infarct size is reported as a percentage of the total range of the left ventricle area at risk (AAR) using the Alpha View gel image analysis software (Alpha Ease FC, USA). Coronary transudate (2 mL) was collected at T0 and T4, and centrifuged for 15 min at 1800 g and 4°C. cTnI concentrations in the coronary transudate were detected using cTnI ELISA kits (Xitang Biotechnology Company, China).

Protein extraction and Western blot analysis
The hearts were kept frozen at −80°C in liquid nitrogen until analysis. Lysis buffer and phosphatase inhibitor- 
extracted proteins were added, and the tissues were homogenized by low-temperature cracking using ultra- 
sonication. The protein content of the samples was 
determined using a bicinchoninic acid assay kit (P0010, 
Biyuntian Biotechnology Company, China) and the protein 
content of the lysate was adjusted to the same concen- 
tration. The lysates were heated for 5 min in a 97°C water 
bath and 20 μg of each sample was electrophoresed in 12% polyacrylamide gels (Bio-Rad, USA) to isolate the 
proteins, which were then transferred onto nitrocellulose 
membranes (Millipore Company, USA). The proteins were 
blocked with 5% skim milk for 2 h. The samples were incubated overnight at 4°C with anti-p-PKC-ε (1:1000; ab63387, Abcam, USA) and anti-caspase-8 (1:1000; D35G2, Santa Cruz, USA) antibodies, with glyceralde- 
hyde-3-phosphate dehydrogenase (GAPDH, 1:1000; AG019, Biyuntian Biotechnology Company, China) as 
the internal reference. The membranes were rinsed three 
times with Tris-buffered saline containing Tween-20 and 
incubated with secondary antibodies for 2 h. An enhanced 
luminol-based chemiluminescence kit (34077, Thermo, 
USA) was used for secondary staining. The stained 
nitrocellulose membranes were placed into the light- 
emitting reagent solution (Western blot chemilumines- 
cence reagent AB solution, 0609*025, Merck, Germany) 
and transferred to a dark room. Membranes were read by 
an automatic processor for color development and fixing. 
p-PKC-ε and caspase-8 expression are reported as gray 
density relative to that of GAPDH.

Statistical analysis
The Graph Pad Prism 4.00 statistical software was 
used for statistical processing. Data are reported as 
means±SD. The hemodynamic data were analyzed using 
analysis of variance (ANOVA) for repeated measures and 
one-way ANOVA followed by the Tukey multiple-compar- 
tion test to compare the differences among groups. 
P<0.05 was considered to be statistically significant.

Results
Rats with CO2 accumulation during sevoflurane 
preconditioning and those that developed refractory 
ventricular fibrillation, recurrent arrhythmia, LVSP 
<80 mmHg, HR <200 bpm after 30 min of equilibration 
were excluded from the experiment.

Cardiac function
LVSP, HR, and ±dP/dtmax decreased and LVEDP 
significantly increased in each group during reperfusion 
(P<0.05), compared with the levels during equilibration 
(Table 1). LVSP, HR, and ±dP/dtmax increased and 
LVEDP significantly decreased in the SWOP group 
(P<0.05), compared with those in the I/R group. LVSP, 
HR, and ±dP/dtmax significantly decreased, whereas the 
LVEDP significantly increased in the 5-HD + SWOP group 
(P<0.05), compared with those in the SWOP group. The 
preconditioning effects induced by sevoflurane were 
abolished by 5-HD (P<0.05) and 5-HD alone did not 
influence LVDP during reperfusion compared with its 
effect in the I/R group (P>0.05).

Myocardial infarct size
The myocardial infarcts in the SWOP group (25 ±4%) 
were smaller (P<0.05) than those in the I/R group 
(42 ±5%). The myocardial infarcts in the 5-HD + SWOP 
group (37 ±3%) were smaller (P<0.05) than those in the 
I/R group (42 ±5%), indicating that 5-HD negated the 
effects of sevoflurane. However, 5-HD itself did not
influence the myocardial infarct size compared with the I/R group (P < 0.05). The differences in size among the other groups were not statistically significant (P > 0.05). The results are shown in Figure 1.

**Concentration of cTnI**

The cTnI concentration in coronary transudate was higher in the I/R (892 ± 27), SWOP (617 ± 29), and 5-HD + SWOP groups (837 ± 26) than in the CON group (498 ± 26). The cTnI concentration in the coronary transudate from the I/R group (892 ± 27) was higher than that in the SWOP (617 ± 29) and in the SEVO groups (501 ± 23; P < 0.05). The cTnI concentration in the coronary transudate from the 5-HD + SWOP group (837 ± 26) was higher (P < 0.05) than that in the SWOP group (617 ± 29), indicating that 5-HD negated the effects of sevoflurane; however, 5-HD alone did not influence the coronary transudate cTnI concentration compared with the I/R group (P > 0.05). Statistically significant differences were not observed among the other groups (P > 0.05).

**Table 1. Hemodynamic parameters.**

<table>
<thead>
<tr>
<th></th>
<th>Baseline (T0)</th>
<th>Reperfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30 min (T1)</td>
<td>60 min (T2)</td>
</tr>
<tr>
<td><strong>HR (min⁻¹)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CON</td>
<td>263 ± 25</td>
<td>256 ± 28</td>
</tr>
<tr>
<td>I/R</td>
<td>272 ± 34</td>
<td>223 ± 18*</td>
</tr>
<tr>
<td>SEVO</td>
<td>257 ± 29</td>
<td>254 ± 26*</td>
</tr>
<tr>
<td>SWOP</td>
<td>255 ± 22</td>
<td>240 ± 25**</td>
</tr>
<tr>
<td>5-HD + SWOP</td>
<td>261 ± 28</td>
<td>228 ± 18**</td>
</tr>
<tr>
<td>5-HD</td>
<td>275 ± 30</td>
<td>225 ± 21**</td>
</tr>
<tr>
<td><strong>LVSP (mmHg)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CON</td>
<td>119 ± 13</td>
<td>111 ± 12</td>
</tr>
<tr>
<td>I/R</td>
<td>117 ± 15</td>
<td>79 ± 9*</td>
</tr>
<tr>
<td>SEVO</td>
<td>125 ± 11</td>
<td>100 ± 12*</td>
</tr>
<tr>
<td>SWOP</td>
<td>115 ± 13</td>
<td>104 ± 10*</td>
</tr>
<tr>
<td>5-HD + SWOP</td>
<td>114 ± 14</td>
<td>82 ± 11*</td>
</tr>
<tr>
<td>5-HD</td>
<td>117 ± 16</td>
<td>78 ± 10**</td>
</tr>
<tr>
<td><strong>LVEDP (mmHg)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CON</td>
<td>6.4 ± 1.3</td>
<td>10.6 ± 7.6*</td>
</tr>
<tr>
<td>I/R</td>
<td>6.3 ± 1.5</td>
<td>45.8 ± 9.6*</td>
</tr>
<tr>
<td>SEVO</td>
<td>5.9 ± 0.9</td>
<td>11.2 ± 8.9*</td>
</tr>
<tr>
<td>SWOP</td>
<td>6.9 ± 1.1</td>
<td>25.1 ± 5.9*</td>
</tr>
<tr>
<td>5-HD + SWOP</td>
<td>6.1 ± 1.0</td>
<td>48.1 ± 7.0*</td>
</tr>
<tr>
<td>5-HD</td>
<td>6.7 ± 1.6</td>
<td>47.8 ± 8.6*</td>
</tr>
<tr>
<td><strong>+dp/dtmax (mmHg/s)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CON</td>
<td>3892 ± 184</td>
<td>2765 ± 159*</td>
</tr>
<tr>
<td>I/R</td>
<td>3780 ± 196</td>
<td>1855 ± 152*</td>
</tr>
<tr>
<td>SEVO</td>
<td>3762 ± 164</td>
<td>2876 ± 127*</td>
</tr>
<tr>
<td>SWOP</td>
<td>3802 ± 164</td>
<td>2755 ± 139*</td>
</tr>
<tr>
<td>5-HD + SWOP</td>
<td>3681 ± 186</td>
<td>1875 ± 132*</td>
</tr>
<tr>
<td>5-HD</td>
<td>3826 ± 221</td>
<td>1808 ± 134*</td>
</tr>
<tr>
<td><strong>−dp/dtmax (mmHg/s)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CON</td>
<td>2907 ± 199</td>
<td>2853 ± 120*</td>
</tr>
<tr>
<td>I/R</td>
<td>2721 ± 268</td>
<td>1009 ± 110*</td>
</tr>
<tr>
<td>SEVO</td>
<td>2877 ± 189</td>
<td>2793 ± 124*</td>
</tr>
<tr>
<td>SWOP</td>
<td>2807 ± 193</td>
<td>1282 ± 111*</td>
</tr>
<tr>
<td>5-HD + SWOP</td>
<td>2648 ± 168</td>
<td>1106 ± 147*</td>
</tr>
<tr>
<td>5-HD</td>
<td>2820 ± 173</td>
<td>1059 ± 162*</td>
</tr>
</tbody>
</table>

Data are reported as means ± SD (n = 9/group). * P < 0.05 vs T0; † P < 0.05 vs I/R group; ‡ P < 0.05 vs SWOP group (one-way ANOVA). HR: heart rate; LVSP: left ventricular peak pressure; LVEDP: left ventricular end diastolic pressure; + dp/dtmax: maximum rate of rise of left ventricular pressure; –dp/dtmax: maximum descending rate of left ventricular pressure; CON: control; I/R: ischemia/reperfusion; SEVO: sevoflurane; SWOP: second window of protection; 5-HD: 5-hydroxydecanoate.
The results are shown in Figure 2.

### Western blots

Before development of ischemia, p-PKC-ε expression was upregulated in the SEVO and SWOP groups compared with the CON and I/R groups (P<0.05), and p-PKC-ε was downregulated in the 5-HD+SWOP group (P<0.05) compared with the SWOP group. 5-HD downregulated p-PKC-ε expression, but 5-HD alone did not influence p-PKC-ε expression compared with expression in the I/R group (P>0.05). The results are shown in Figures 3 and 4.

After reperfusion, p-PKC-ε expression was upregulated in the SEVO group compared with the CON group (P<0.05), but there were no statistically significant differences in expression among the I/R, SWOP, and 5-HD+SWOP groups (P>0.05). Caspase-8 expression was downregulated during reperfusion in the SWOP group (P<0.05) compared with the I/R group. Caspase-8 expression was upregulated during reperfusion in the 5-HD+SWOP group (P<0.05) compared with the SWOP group. 5-HD alone did not influence caspase-8 expression compared with that in the I/R group (P>0.05). The results are shown in Figures 3 and 4.

### Discussion

This study showed that delayed sevoflurane preconditioning reduced myocardial infarct sizes and protected against myocardial ischemia/reperfusion (I/R) injury in isolated rats. The mitoKATP channel played an important role in triggering the upregulation of p-PKC-ε as well as the downregulation of the anti-apoptotic protein caspase-8, thereby decreasing the severity of myocardial I/R injury.

APC occurs within a few hours (2-3 h in the early stages) to within a few days before ischemia, reaches a peak in approximately 24 to 48 h and persists for 72 h (18). Konia (19) reported that inhalation of 2.5% sevoflurane for 1 h reduces I/R injury in rats. The results of the blood gas analysis prior to sevoflurane preconditioning confirmed that the rats in this study had normal blood gas concentrations. The transudate cTnI concentrations increased during reperfusion compared with those in the equilibrium phase and their infarct sizes remained within a certain range of difference, which indicated the successful establishment of the Langendorff isolated heart perfusion model.

Sevoflurane is a new inhalational anesthetic that is widely used clinically and has been recommended for routine use during noncardiac surgery for patients with a risk of myocardial infarction. Sevoflurane affects the dynamics of human blood, heart rate, and sympathetic nerve activity, and it has a low blood-gas partition coefficient (0.63). Recovery after discontinuation is rapid, but with respiratory tract irritation. Sevoflurane is highly stable and superior to other anesthetics. Lutz (20) reported that 2.5% sevoflurane pretreatment before myocardial ischemia significantly improves cardiac function. Chiari et al. (21) reported that intravenous emulsified sevoflurane has both an early and a delayed myocardial protective effect; however, the mechanism of this delayed protective effect is unclear (19).

LVEDP reflects left ventricular compliance, whereas LVSP reflects left ventricular systolic function. LVEDP was decreased, whereas LVDP, LVSP, HR, and ±dP/dtmax were increased during reperfusion in the SWOP group compared with those in the I/R group, which suggest that the protective effect of delayed sevoflurane preconditioning significantly improves both diastolic and systolic cardiac function. LVEDP was increased, whereas

---

**Figure 1.** Myocardial infarct size after 2 h of reperfusion. AAR: area at risk; I/R: ischemia/reperfusion; SWOP: second window of protection; 5-HD: 5-hydroxydecanoate. *P<0.05 vs I/R group; †P<0.05 vs SWOP group (one-way ANOVA).

**Figure 2.** Concentration of coronary transudate cTnI after 2 h of reperfusion. cTnI: cardiac troponin I; CON: control; I/R: ischemia/reperfusion; SEVO: sevoflurane; SWOP: second window of protection; 5-HD: 5-hydroxydecanoate. *P<0.05 vs CON group; †P<0.05 vs I/R group; ‡P<0.05 vs SWOP group (one-way ANOVA).
LVDP, LVSP, HR, and ±dP/dtmax were decreased during reperfusion in the 5-HD group compared with those in the SWOP group, which suggest that mitoKATP is involved in the protective effect of delayed sevoflurane preconditioning.

Myocardial infarct size is the gold standard for measuring myocardial I/R injury. The infarcts in the SWOP group were smaller than those in the I/R group, which indicates that sevoflurane pretreatment has a delayed protective effect against I/R injury in isolated perfused rat hearts. The infarcts in the SWOP group were larger than those in the 5-HD + SWOP group, which suggests that mitoKATP is involved in the protective effect of delayed sevoflurane preconditioning.

MitoKATP channels are present in the mitochondrial membranes of myocardial cells, and they function during tissue ischemia as hypoxia protection effectors (9). MitoKATP channels act as influx rectifier potassium channels activated by intracellular nucleoside diphosphate, whereas intracellular ATP inhibits their opening. Under normal physiological conditions, the KATP channel is closed, but myocardial ischemia, decreased intracellular ATP concentration, and ischemic metabolite accumulation causes membrane hyperpolarization cardiac action potential duration (APD) shortening, calcium currents, and decreased myocardial contractility that trigger the opening of KATP channels. MitoKATP channels are present in the mitochondrial membrane, and are activated by hypoxia metabolites known as hypoxia-induced effectors to protect tissues from injury. Calcium release reduced apoptosis after ischemia-reperfusion injury (22). Studies have shown that the opening of mitoKATP channels is triggered and/or mediated during the early stages of inhalational anesthetic preconditioning (23-25). In the current study, 5-HD, a specific inhibitor of the mitoKATP channels, weakened the protective effect of sevoflurane, which demonstrates that mitoKATP channels are involved in the protective effect of sevoflurane. cTnI is a cardiac myocyte-specific marker for myocardial injury that occurs at different concentrations. cTnI is a sensitive indicator of myocardial injury. The concentrations of coronary transudate cTnI were higher, and myocardial infarct sizes were larger, in the 5-HD + SWOP group than in the SWOP group. This result shows that inhibition of mitoKATP channels increases the cTnI transudate concentration and the myocardial infarct size. Therefore, mitoKATP channels triggered the protective effect of sevoflurane preconditioning.

Figure 3. p-PKC-ε expression before ischemia (A,C) and 2 h after reperfusion (B,D). p-PKC-ε: phosphorylated protein kinase C-ε; CON: control; I/R: ischemia/reperfusion; SEVO: sevoflurane; SWOP: second window of protection; 5-HD: 5-hydroxydecanoate. *P<0.05 vs CON; †P<0.05 vs I/R group; ‡P<0.05 vs SWOP group (one-way ANOVA).

Figure 4. Caspase-8 protein expression before ischemia (A,C) and 2 h after reperfusion (B,D). CON: control; I/R: ischemia/reperfusion; SEVO: sevoflurane; SWOP: second window of protection; 5-HD: 5-hydroxydecanoate. *P<0.05 vs CON; †P<0.05 vs I/R group; ‡P<0.05 vs SWOP group (one-way ANOVA).
MitoK\textsubscript{ATP} channels mediate the effects of inhaled anesthetic preconditioning by activating G protein-coupled receptors and the intracellular signal transduction pathway, as well as the translocation of PKC-\(\varepsilon\) (9). Studies have shown that G protein-coupled receptor agonists such as adenosine, opioids, and bradykinin reduce the cell infarction size range (26). Ischemic and pharmacological preconditioning activates PKC (27), protein tyrosine kinase (PTK) (26), and mitogen-activated protein kinases (MAPK) (28). APC occurs in organs such as the brain, heart, liver, small intestines, skeletal muscles, kidneys, and lungs. The possible mechanisms of APC include glutamate, adenosine receptor activation mechanisms, mitoK\textsubscript{ATP} channels, nitric oxide, oxidative stress, and low temperature mechanisms. The low temperature mechanisms include those that involve protein kinase C, which is released by a series of signal transduction mechanisms. As a novel protein kinase C, PKC-\(\varepsilon\) plays an important role in the development of ischemic tolerance. Myocardial ischemia tolerance is dependent on PKC activation, especially on the activation of PKC-\(\varepsilon\) (29). Novalija et al. (29) reported that the PKC-\(\varepsilon\) inhibitor PP-149 counteracts the myocardial protective effects of sevoflurane pretreatment in Langendorff models, confirming the role of sevoflurane in PKC-\(\varepsilon\)-mediated myocardial protection. Weber et al. (30) reported that xenon exerts its myocardial protective effect by increasing PKC-\(\varepsilon\) expression. That effect is blocked by 5-HD, which suggests that PKC-\(\varepsilon\) is the downstream target of mitoK\textsubscript{ATP} channels. The degree of PKC-\(\varepsilon\) phosphorylation was lower before myocardial ischemia, which suggests that mitoK\textsubscript{ATP} channels trigger the delayed protective effect of sevoflurane by increasing PKC-\(\varepsilon\) phosphorylation.

Myocardial ischemia causes cell necrosis, which delays myocardial apoptosis. Delayed anesthetic preconditioning protects against myocardial infarction by down-regulating caspase-3 (31). Apoptosis is gene-controlled programmed cell death (32) and is regulated by genes and proteins such as Bcl-2, caspase-3, and caspase-8. Caspases are essential in the apoptotic process. Caspase-8 is usually secreted as a zymogen. Once activated, caspase-8 causes the cleavage and activation of caspase-3, caspase-6, and caspase-7, resulting in apoptosis (2). Apoptosis is an irreversible cascade of limited substrate hydrolysis of caspases (33,34). Sevoflurane inhibits the production of reactive oxygen species and activates Bcl-2 by stimulating K\textsubscript{ATP} channel opening, thereby preventing apoptosis (35). The pro-apoptotic protein caspase-8 is an upstream promoter that controls the death receptor-mediated apoptosis pathway (36). Considering that 5-HD concentrations were increased before sevoflurane preconditioning, caspase-8 protein expression was elevated during reperfusion. Inhibition of mitoK\textsubscript{ATP} channels promoted myocardial cell apoptosis. Thus, caspase-8 is an ideal target for inhibiting apoptosis.

We only used sevoflurane in the current study; thus, we do not know whether all of the volatile anesthetics are equally effective for IPC. A previous study has demonstrated the efficacy of IPC in human surgical series (2). Most of the study focused on the acute phase of protection, not on delayed protection against I/R injury, which occurs 12 to 24 h after preconditioning. Two types of K\textsubscript{ATP} channels are present in myocardial cells, membrane-bound channels or cell membrane K\textsubscript{ATP} channel (sarcK\textsubscript{ATP}) and mitochondrial membrane-bound channels or mitoK\textsubscript{ATP}. We used only the mitoK\textsubscript{ATP} channel inhibitor 5-HD in the current study, not the sarcK\textsubscript{ATP} inhibitor HMR-1098 because HMR-1098 is not yet commercially available. We did not find any significant difference in the protective effects of the two channels and did not distinguish between the specific mechanisms of the two channels. Finally, we did not investigate the pharmacokinetics and pharmacodynamics of 5-HD and only based the dosage and timing of 5-HD on previously published studies.

In summary, sevoflurane preconditioning exerted a delayed protective effect against myocardial I/R injury in isolated hearts. The mechanism involved mitoK\textsubscript{ATP} channels, which regulate the phosphorylation of p-PKC-\(\varepsilon\) before ischemia and down-regulate caspase-8 during reperfusion.

**Acknowledgments**

Research supported by the Natural Science Foundation of Jiangsu Province (grant #BK20141187 to C. Wang), and by the Technology Bureau of Suzhou, China (grant #SYS201473 to S.G. Qiao). C. Wang also received support from the Project of Gusu Health Key Talent.


